Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-12
2005-04-12
Davis, Zinna Northington (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S154000
Reexamination Certificate
active
06878722
ABSTRACT:
The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
REFERENCES:
patent: 5633388 (1997-05-01), Diana et al.
patent: 5866684 (1999-02-01), Attwood et al.
patent: 5869253 (1999-02-01), Draper
patent: 6018020 (2000-01-01), Attwood et al.
patent: 6225284 (2001-05-01), Albert et al.
patent: 6265380 (2001-07-01), Tung et al.
patent: 6268207 (2001-07-01), Bailey
patent: 6323180 (2001-11-01), Linas-Brunet et al.
patent: 6410531 (2002-06-01), Linas-Brunet et al.
patent: 6420380 (2002-07-01), Linas-Brunet et al.
patent: 6534523 (2003-03-01), Linas-Brunet et al.
patent: 20020111313 (2002-08-01), Campbell et al.
patent: WO 9533764 (1995-12-01), None
patent: WO 9706804 (1997-02-01), None
patent: WO 9743310 (1997-11-01), None
patent: WO 9817679 (1998-04-01), None
patent: WO 9822496 (1998-05-01), None
patent: WO 9846597 (1998-10-01), None
patent: WO 9846630 (1998-10-01), None
patent: WO 9907733 (1999-02-01), None
patent: WO 9907734 (1999-02-01), None
patent: WO 9938888 (1999-08-01), None
patent: WO 9950230 (1999-10-01), None
patent: WO 9964442 (1999-12-01), None
patent: WO 0006529 (2000-02-01), None
patent: WO 0009543 (2000-02-01), None
patent: WO 0009558 (2000-02-01), None
patent: WO 0010573 (2000-03-01), None
patent: WO 0013708 (2000-03-01), None
patent: WO 0018231 (2000-04-01), None
patent: WO 0059929 (2000-10-01), None
patent: 1162196 (2000-12-01), None
patent: WO 0132153 (2001-05-01), None
patent: WO 0185172 (2001-11-01), None
patent: WO 0204425 (2002-01-01), None
patent: WO 0206246 (2002-01-01), None
patent: WO 02060926 (2002-08-01), None
patent: WO 03064416 (2003-08-01), None
patent: WO 03064455 (2003-08-01), None
patent: WO 03064456 (2003-08-01), None
patent: WO 03066103 (2003-08-01), None
Lauer et al. (2001) New England Journal of Medicine, vol. 345 No. 1, pp. 41-52.
Zeuzem et al. (2000) The New England Journal of Medicine, vol. 343 No. 23, pp. 1666-1672.
Poynard et al. (1998) The Lancet, vol. 352, pp. 1426-1432.
Poupart et al. (2001) The Journal of Organic Chemistry, vol. 66 No. 14, pp. 4743-4751.
Steinkuhler et al. (1998) Biochemistry, vol. 37, pp. 8899-8905.
Ingallinella et al. (1998) Biochemistry, vol. 37, pp. 8906-8914.
Chu et al. (1996) Tetrahedron Letters, vol. 37 No. 40, pp. 7229-7232.
Matsumoto et al. (1996) Antiviral Research, vol. 30 No. 1, p. A23, Abstract 19.
Campbell Jeffrey Allen
D'Andrea Stanley
Good Andrew
Li Jianqing
Mcphee Fiona
Bristol--Myers Squibb Company
Davis Zinna Northington
Volles Warren K.
LandOfFree
Substituted cycloalkyl P1′ hepatitis C virus inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted cycloalkyl P1′ hepatitis C virus inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted cycloalkyl P1′ hepatitis C virus inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3389537